Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P2JR | ISIN: IE00BLP1HW54 | Ticker-Symbol: 4VK
Tradegate
13.02.26 | 16:00
268,70 Euro
-0,81 % -2,20
1-Jahres-Chart
AON PLC Chart 1 Jahr
5-Tage-Chart
AON PLC 5-Tage-Chart
RealtimeGeldBriefZeit
270,00272,2014.02.
270,20271,5013.02.
PR Newswire
733 Leser
Artikel bewerten:
(2)

Aon plc: Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform

Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost adherence, retention and deliver breakthrough health outcomes with cost savings

DUBLIN, Aug. 18, 2025 /PRNewswire/ -- Aon plc (NYSE: AON), a leading global professional services firm, today announced a strategic investment in eMed Population Health, Inc., an emerging leader in the delivery of GLP-1 programs. The partnership will enhance employer sponsored access to GLP-1 therapies and scale solutions for obesity.

The investment follows the launch earlier this year of Aon's subsidized GLP-1 weight management benefit program for its U.S. workforce - developed by eMed - which has delivered strong adherence, high retention and sustainable results for the firm's colleagues. In the sixth months since Aon's program launched, more than 1,200 people have registered and the firm has seen an average of 22.4 pounds lost with a retention rate of 95 percent.

With this investment, eMed will continue to increase distribution of its digital-first healthcare platform - which combines at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and continuous adherence support-to reach more employers and patients.

"As the leader of Aon's People Organization, I know how important it's been to include GLP-1 coverage as part of our own U.S. Total Rewards strategy," said Lisa Stevens, Chief Administrative Officer for Aon. "When you see the benefits it brings to people you work with every day, it really underscores how the decisions employers make today shape the future health and performance of our workforces and our businesses."

Stevens added: "This strategic investment in eMed enables our firm to have an active role in offering a global solution that is focused on medication adherence that will be differentiated in the marketplace in helping employers reduce long-term health costs while improving the quality of life for their people. By aligning innovation with behavior change and accountability, together we can deliver sustainable results at scale."

The collaboration marks a major milestone in eMed's mission to deliver effective and sustainable care through an integrated, data-driven experience, while expanding its provider network, behavioral health tools and market reach.

"Today marks a game-changing partnership between Aon and eMed and is a win for both payers and participants," said Linda Yaccarino, CEO of eMed Population Health, Inc. "Our shared vision of market transformation is validated and accelerated by the investment from Aon. This strategic investment in eMed further enables our firm to play an active role in offering a differentiated global solution focused on medication adherence - helping employers reduce long-term health costs while improving quality of life for their people."

Aon continues to build a complimentary suite of GLP-1 solutions, industry-leading experience and advisory capabilities for clients. In April, Aon unveiled findings from its multi-year analysis of U.S. commercial health claims data, which evidenced the transformative potential of GLP-1 medications in managing obesity and improving health outcomes.

"The rise of GLP-1 medications and its cost has sparked significant strategic considerations from employers looking to address obesity and other chronic conditions," said Farheen Dam, Head of Health for North America at Aon. "We know that GLP-1s are not a one size fits all strategy. This is why data, modelling and strategic guidance from our clinical, actuarial and pharmacy teams help employers build GLP-1s strategies that fit their population and objectives."

About eMed
eMed® is the world's first end-to-end GLP-1 care platform built on Empathetic AI. From remote diagnostics and clinician-led prescriptions to adherence coaching and insights, eMed empowers employers to manage population health with accountability and compassion. Learn more at www.eMed.com.

About Aon
Aon plc (NYSE: AON) exists to shape decisions for the better - to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses.

Follow Aon on?LinkedIn,?X,?Facebook?and?Instagram.?Stay up-to-date by visiting Aon's?newsroom and sign up for news alerts?here.

Media Contacts

eMed
Matt Gorman
mgorman@targetedvictory.com

Aon
mediainquiries@aon.com
Toll-free (U.S., Canada and Puerto Rico): +1 833 751 8114
International: +1 312 381 3024

Aon plc (NYSE: AON) exists to shape decisions for the better - to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues in over 120 countries provide our clients with the clarity and confidence to make better risk and people decisions that protect and grow their businesses. Follow Aon on LinkedIn, X, Facebook and Instagram. Stay up-to-date by visiting Aon's newsroom and sign up for news alerts here.

Logo - https://mma.prnewswire.com/media/1632623/Aon_Logo_2.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/aon-announces-strategic-investment-in-emed-to-scale-glp-1-population-health-platform-302532187.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.